CMPX

Company Overview — What Does Compass Therapeutics, Inc. Do?

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops proprietary antibody-based therapeutics to treat multiple human diseases. The company's product candidates include CTX-009, an investigational bispecific antibody, which is in Phase II clinical trial for biliary tract cancers, as well as Phase Ib clinical trial for colorectal and ovarian cancer; CTX-471, a monoclonal antibody product candidate that is in Phase I clinical trial for patients with solid tumors, such as small cell lung cancer and melanoma; and CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 for oncology area. The company was founded in 2014 and is headquartered in Boston, Massachusetts. Compass Therapeutics, Inc. (CMPX) is classified as a small-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Thomas J. Schuetz and employs approximately 20 people. With a market capitalization of $978M, CMPX is one of the notable companies in the Healthcare sector.

Compass Therapeutics, Inc. (CMPX) Stock Rating — Hold (April 2026)

As of April 2026, Compass Therapeutics, Inc. receives a Hold rating with a composite score of 39.0/100 and 3 out of 5 stars from the Blank Capital Research quantitative model.CMPX ranks #1,754 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Compass Therapeutics, Inc. ranks #178 of 838 stocks, placing it in the top quartile of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

CMPX Stock Price and 52-Week Range

Compass Therapeutics, Inc. (CMPX) currently trades at $5.21. The stock lost $0.24 (4.4%) in the most recent trading session. The 52-week high for CMPX is $6.88, which means the stock is currently trading -24.3% from its annual peak. The 52-week low is $1.33, putting the stock 291.7% above its annual trough. Recent trading volume was 3.2M shares, reflecting moderate market activity.

Is CMPX Overvalued or Undervalued? — Valuation Analysis

Compass Therapeutics, Inc. (CMPX) carries a value factor score of 26/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 4.86x, versus the sector average of 2.75x.

At current multiples, Compass Therapeutics, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Compass Therapeutics, Inc. Profitability — ROE, Margins, and Quality Score

Compass Therapeutics, Inc. (CMPX) earns a quality factor score of 16/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -31.1%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -27.9% versus the sector average of -33.1%.

Revenue growth is running at -100.0% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

CMPX Debt, Balance Sheet, and Financial Health

Compass Therapeutics, Inc. has a debt-to-equity ratio of 12.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 15.02x, indicating strong short-term liquidity. Total debt on the balance sheet is $0. Cash and equivalents stand at $46M.

CMPX has a beta of 1.19, meaning it is roughly in line with the broader market in terms of price volatility. The stability factor score for Compass Therapeutics, Inc. is 38/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Compass Therapeutics, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Compass Therapeutics, Inc. reported revenue of $0 and earnings per share (EPS) of $-0.42. Net income for the quarter was $-61M. Operating income came in at $-67M.

In FY 2025, Compass Therapeutics, Inc. reported revenue of $0 and earnings per share (EPS) of $-0.42. Net income for the quarter was $-66M. Operating income came in at $-73M.

In Q3 2025, Compass Therapeutics, Inc. reported revenue of $0 and earnings per share (EPS) of $-0.08. Net income for the quarter was $-14M. Operating income came in at $-16M.

In Q2 2025, Compass Therapeutics, Inc. reported revenue of $0 and earnings per share (EPS) of $-0.14. Net income for the quarter was $-20M. Operating income came in at $-21M.

Over the past 8 quarters, Compass Therapeutics, Inc. has experienced revenue contraction from $850,000 to $0. Investors analyzing CMPX stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

CMPX Dividend Yield and Income Analysis

Compass Therapeutics, Inc. (CMPX) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

CMPX Momentum and Technical Analysis Profile

Compass Therapeutics, Inc. (CMPX) has a momentum factor score of 69/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 40/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 53/100 reflects moderate short selling activity.

CMPX vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Compass Therapeutics, Inc. (CMPX) ranks #178 out of 838 stocks based on the Blank Capital composite score. This places CMPX in the top quartile of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing CMPX against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full CMPX vs S&P 500 (SPY) comparison to assess how Compass Therapeutics, Inc. stacks up against the broader market across all factor dimensions.

CMPX Next Earnings Date

No upcoming earnings date has been announced for Compass Therapeutics, Inc. (CMPX) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy CMPX? — Investment Thesis Summary

Compass Therapeutics, Inc. presents a balanced picture with arguments on both sides. The quality score of 16/100 flags below-average profitability. The value score of 26/100 indicates premium valuation. Price momentum is positive at 69/100, suggesting the trend favors buyers. High volatility (stability score 38/100) increases portfolio risk.

In summary, Compass Therapeutics, Inc. (CMPX) earns a Hold rating with a composite score of 39.0/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on CMPX stock.

Related Resources for CMPX Investors

Explore more research and tools: CMPX vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare CMPX head-to-head with peers: CMPX vs AZN, CMPX vs SLGL, CMPX vs VMD.